Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
Nascent Biotech Inc. Stock Analysis NBIO
United States N/A Nano Cap Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The firm's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.
Read More Nascent Biotech Inc (NBIO) Chart
Key Statistics of Nascent Biotech Inc (NBIO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
16.10KP/E Ratio (TTM)
-52 Week Range
Market Cap
51.66KAvg. Volume
3625.50Dividend Yield
-Financial Metrics & Statements of Nascent Biotech Inc (NBIO)
FAQ's for Nascent Biotech Inc (NBIO)
- According to Musaffa’s Shariah screening methodology, Nascent Biotech Inc (NBIO) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nascent Biotech Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Nascent Biotech Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Nascent Biotech Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Nascent Biotech Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Nascent Biotech Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.